Navigation Links
Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C

BARCELONA, Spain--(BUSINESS WIRE)--Apr 14, 2007 - In a late-breaker presentation at the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL), researchers today presented data from a planned interim analysis of the PROVE 1 clinical trial, which is the first trial to evaluate short-duration therapy with the investigational hepatitis C protease inhibitor telaprevir (TVR, VX-950) in combination with pegylated interferon (peg-IFN) and ribavirin (RBV) in treatment-naive, genotype 1-infected hepatitis C patients. The data from PROVE 1 demonstrated a high rate of rapid viral response (RVR) in the telaprevir groups and a low rate of on-treatment viral breakthrough, and suggested that 12 weeks of telaprevir-based therapy enabled some patients to clear the virus. Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) is developing telaprevir in collaboration with Tibotec.

"The high rates of RVR observed in the telaprevir groups in PROVE 1, and the fact that some patients have remained persistently viral negative 20 weeks after stopping the 12 weeks of telaprevir-based therapy, suggest that we may be able to shorten the treatment duration in genotype 1 HCV patients," said John McHutchison, M.D., Principal Investigator for the PROVE 1 study and Director of Gastroenterology and Hepatology Research at Duke Clinical Research Institute. "These interim results are encouraging and suggest that high sustained viral response (SVR) rates may be achieved with regimens that are 24 weeks in total duration. We look forward to 24 week follow-up data from the initial group of patients who stopped treatment at 12 weeks, and follow-up data from patients in the study who received 24 weeks of treatment."

PROVE 1 Summary

-- 88% and 79% of patients receiving telaprevir achieved a rapid viral response (RVR) as measured by plasma HCV RNA (less than)30 IU/mL and (less than)10 IU/mL, respectively, at 4 weeks.<
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
(Date:7/22/2014)... 22, 2014  Nektar Therapeutics (Nasdaq: NKTR ) ... June 30, 2014 on Thursday, July 31, 2014, after the ... and chief executive officer, will host a conference call to ... p.m. Pacific Time (PT). The press release ... be accessed through a link that is posted on the ...
(Date:7/22/2014)... July 22, 2014 Cumberland Pharmaceuticals Inc. (NASDAQ: ... 2014 financial results after the market closes on Tuesday, ... webcast will be held on Tuesday, August 5, 2014, ... To participate in the call, please dial ... A rebroadcast of the teleconference will be available for ...
(Date:7/22/2014)... 22, 2014 Research and Markets ... Market by Equipment, by Reagent, by Application - Global ... http://photos.prnewswire.com/prnh/20130307/600769 Biopharmaceuticals ... is one of the most important and widely used ... application segment of the cell culture market in 2013. ...
Breaking Medicine Technology:Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets 2Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets 3Cumberland Pharmaceuticals To Announce Second Quarter 2014 Financial Results On August 5, 2014 2Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 2Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 3
... Permanente leads the nation among all reporting commercial health ... conclusions were based on information in the 2010 National ... Kaiser Permanente received top marks for: ... Appropriate treatment for children with upper respiratory infection ...
... 11 More than 170 industry experts and thought ... executive workshops at AdvaMed 2010: The MedTech Conference ... fourth year, this annual medical technology industry developed and ... and around the world.   "This conference ...
Cached Medicine Technology:Kaiser Permanente Leads the Nation in 12 Quality Measures 2Kaiser Permanente Leads the Nation in 12 Quality Measures 3Medical Technology, Funding & Government Experts Address Business, Investment, Reimbursement, Compliance, Innovation, Regulatory and Legal Issues at AdvaMed 2010 2Medical Technology, Funding & Government Experts Address Business, Investment, Reimbursement, Compliance, Innovation, Regulatory and Legal Issues at AdvaMed 2010 3
(Date:7/23/2014)... --- Controlling pain during childbirth and post delivery may ... M.D., a Northwestern Medicine perinatal psychiatrist, in a July ... , Wisner,s editorial is based on a new Chinese ... epidural anesthesia during a vaginal delivery had a much ... have the epidural. , "Maximizing pain control in labor ...
(Date:7/22/2014)... Kansas City, MO (PRWEB) July 22, 2014 ... cheap Sporting Kansas City vs. Manchester City tickets at ... match will take place on Wednesday, July 23rd. Tickets ... up to game time. Ticket Down can be reached ... City vs. Manchester City are authentic and covered by Ticket ...
(Date:7/22/2014)... CA (PRWEB) July 22, 2014 As ... products for consumers to buy can now reduce or ... News company has released its cosmetic buying guide to ... eyes at http://cherrynews.com/best-nourishing-eye-serum . , This guide is ... suffer from the different under eye circles that can ...
(Date:7/22/2014)... July 22, 2014 DocbookMD , ... of deploying one of the largest physician-centric mobile communication ... MHMD ) in Houston. , Created by Austin-based physicians, ... DocbookMD application will be embedded into MHMD’s Accountable Care ... for the best technology to put this capability at ...
(Date:7/22/2014)... Beach, FL (PRWEB) July 22, 2014 ... that they are now an authorized Daikin comfort pro ... and install Daikin indoor heating and cooling system equipment. ... each one is thoroughly reviewed before being approved. , ... an innovator in the Split System Air Conditioning Market. ...
Breaking Medicine News(10 mins):Health News:Controlling childbirth pain tied to lower depression risk 2Health News:Sporting Kansas City vs. Manchester City Tickets: Ticket Down Has Slashed Ticket Prices for Manchester City vs. Sporting Kansas City on July 23rd 2Health News:Remove Dark Circles Under Eyes: New Cosmetic Buying Guide Released Online for Men and Women 2Health News:Memorial Hermann Physician Network Launches Physician Mobile Communication Solution Throughout Houston 2Health News:Memorial Hermann Physician Network Launches Physician Mobile Communication Solution Throughout Houston 3Health News:Memorial Hermann Physician Network Launches Physician Mobile Communication Solution Throughout Houston 4Health News:Air Conditioning & Heating Inc. Now an Authorized Daikin Comfort Pro Dealer 2
... Toy Puppies to the Obama Daughters , , ... President-Elect Obama,s first promise: to get a family dog. But ... kept the new first-dad from making a decision. So, in ... donating 2 "asthma & allergy friendly" toy puppies to the Obama ...
... with imaging exam results may enable a more meticulous ... as a more personal and empathetic approach, according to ... the Radiological Society of North America (RSNA). , ... being and not as an anonymous case study," said ...
... the connection between second-hand smoke and coronary heart disease ... such passive smoking, exposures have been reduced. In an ... American Journal of Preventive Medicine , researchers from ... and Columbia University have recalibrated the CHD Policy Model ...
... Ensign Group, Inc.,(Nasdaq: ENSG ) announced that ... successfully graduated from the Centers for Medicare and,Medicaid Services, ... (Logo: http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO ) , ... Laurie House, Director of Nursing at Pocatello Care,& Rehabilitation ...
... the face of one of the most,severe economic downturns ... of,Directors has approved an investment of up to a ... Employee pension plans, which are,often heavily invested in stocks ... nation,s worsening economy. Although conservatively,invested, the Sutter Health Retirement ...
... of higher mortality and lower surgery rates in women ... may be related to the complexity of evaluating the ... Mayo Clinic study published this month in the ... affects approximately 150 million people worldwide and often requires ...
Cached Medicine News:Health News:Asthma and Allergy Foundation Helps New First-Dad Keep His First Promise 2Health News:Patient photos spur radiologist empathy and eye for detail 2Health News:The Ensign Group Successfully Graduates Second Nursing Home From CMS Special Focus Program 2Health News:The Ensign Group Successfully Graduates Second Nursing Home From CMS Special Focus Program 3Health News:Sutter Health Invests Hundreds of Millions in Employee Pension 2Health News:Women with mitral valve prolapse are treated less aggressively than men and may be at high risk 2
... patient ID verification and laboratory specimen labeling system ... the phlebotomist or nurse, the identity of the ... verification is made, a bar coded sample ID ... unique design simplifies and eliminates the interface problems ...
... Horizon Admin-Rx is a bar-code medication administration ... medication administration process with bar-code technology. Caregivers ... handheld or laptop device to verify that ... at the right time in the right ...
... MedPoint™, a Medication Administration Control ... positive assurance that they are administering ... When used with a bar coded ... MedPoint extends the benefits of the ...
... When it comes to medication administration, ... afford to make. The solution is the ... a highly-scalable bar-coded medication administration system, suitable ... also be used stand-alone, networked, or as ...
Medicine Products: